Efficacy and Safety of an Artificial-pancreas-like Learning-based Control in Type 1 Diabetes on Multiple Daily Injection Therapy

NANot yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

March 30, 2025

Study Completion Date

June 30, 2025

Conditions
Diabetes Mellitus, Type 1
Interventions
DEVICE

AP-A Dosage Decision Support System

The AP-A Dosage Decision Support System represents a new solution in diabetes care, offering customized insulin dosage recommendations to patients. This system is a product of integrating four pivotal modules: the individualized model learning module, the risk-sensitive control module, the Bayesian optimization module, and the safety constraint module. Together, they establish a robust framework that employs advanced computational methodologies to deliver precise and personalized insulin dosage guidance, significantly improving the effectiveness and safety of diabetes treatment plans. The actual injection dose in the intervention group was executed by the doctor after approval based on the recommendation of the AP-A Dosage Decision Support System.

All Listed Sponsors
collaborator

Hebei Provincial People's Hospital

UNKNOWN

collaborator

Xingtai People's Hospital

OTHER

lead

Peking University People's Hospital

OTHER

NCT06418464 - Efficacy and Safety of an Artificial-pancreas-like Learning-based Control in Type 1 Diabetes on Multiple Daily Injection Therapy | Biotech Hunter | Biotech Hunter